Anthera Pharmaceuticals, Inc.

Equities

ANTH

US03674U3005

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:50:58 2024-04-24 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-98.51%

2018	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	CI
2018	Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	CI

Anthera Pharmaceuticals Announces Resignation of Klara Dickinson-Eason as Senior Vice President, Chief Regulatory Officer, Effective June 20, 2017

June 19, 2017 at 05:22 pm EDT

Anthera Pharmaceuticals announced that on June 14, 2017, Klara Dickinson-Eason tendered her letter of resignation from the role of Senior Vice President, Chief Regulatory Officer, effective June 20, 2017. Ms. Dickinson-Eason will continue to support the company in a key advisory role with respect to the company's regulatory strategy.

Latest news about Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from S&P TMI Index	18-07-02	CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from NASDAQ Composite Index	18-06-27	CI
Anthera Pharmaceuticals, Inc. Reports Top Line Data from the Result Phase 3 Clinical Study of Sollpura	18-03-12	CI
Transcript : Anthera Pharmaceuticals, Inc. - Special Call	18-03-12
Anthera Mulls Acquisitions	18-03-06	CI
Anthera Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2017	18-03-05	CI
Anthera Pharmaceuticals, Inc. Concludes Last Patient Visit in the Phase 3 Result Clinical Study of Sollpura	18-02-05	CI
Anthera Pharmaceuticals, Inc. announced that it has received $15 million in funding from a group of investors	18-01-08	CI
Anthera Pharmaceuticals, Inc. Appoints Patrick Murphy as Senior Vice President, Manufacturing	18-01-03	CI
Anthera Pharmaceuticals, Inc. Announces Positive Outcome of Interim Futility Analysis in the Phase 3 Result Clinical Study of Sollpura	17-12-11	CI
Anthera Pharmaceuticals Announces Completion of Recruitment in the Phase 3 RESULT Clinical Study of Sollpura	17-11-09	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2017	17-11-06	CI
Anthera Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from a group of investors	17-10-22	CI
Anthera Pharmaceuticals, Inc. Announces Top Line Final Data from Phase 2 BRIGHT-SC Study of Blisibimod	17-08-28	CI
Anthera Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017	17-08-09	CI
Anthera Pharmaceuticals, Inc. Announces Executive Changes	17-07-14	CI
Anthera Pharmaceuticals, Inc. Announces Commencement of Screening in European Sites in Phase 3 Result Clinical Study of Sollpura	17-07-06	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 3000 Index	17-06-23	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from Russell 2000 Index	17-06-23	CI
Anthera Pharmaceuticals, Inc.(OTCPK:ANTH) dropped from Russell 2000 Dynamic Index	17-06-23	CI
Anthera Pharmaceuticals Announces Resignation of Klara Dickinson-Eason as Senior Vice President, Chief Regulatory Officer, Effective June 20, 2017	17-06-19	CI
Anthera Pharmaceuticals, Inc.(NasdaqGM:ANTH) dropped from S&P Global BMI Index	17-06-19	CI
Certain Common Stock of Anthera Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2017.	17-06-11	CI
Certain Options of Anthera Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2017.	17-06-11	CI
Certain Warrants of Anthera Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 12-JUN-2017.	17-06-11	CI

Chart Anthera Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANTHERA PHARMACEUTICALS, INC.	-98.51%	26
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs